

Demosthenes E Ziogas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8251082/publications.pdf>

Version: 2024-02-01

110
papers

1,030
citations

567144

15
h-index

454834

30
g-index

110
all docs

110
docs citations

110
times ranked

764
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and patient-monitoring biomarkers: precision in the management of colorectal cancer. <i>Biomarkers in Medicine</i> , 2020, 14, 335-339.	0.6	2
2	From personalized to precision cancer medicine. <i>Personalized Medicine</i> , 2020, 17, 245-250.	0.8	2
3	Genomic and transcriptional heterogeneity-based precision in personalized treatment for breast cancer. <i>Personalized Medicine</i> , 2019, 16, 361-364.	0.8	1
4	Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. <i>Future Oncology</i> , 2019, 15, 1805-1810.	1.1	0
5	Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. <i>Drug Discovery Today</i> , 2019, 24, 1281-1294.	3.2	25
6	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1809.	1.7	17
7	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. <i>Medicinal Research Reviews</i> , 2019, 39, 1205-1227.	5.0	21
8	Next-generation sequencing: from conventional applications to breakthrough genomic analyses and precision oncology. <i>Expert Review of Medical Devices</i> , 2018, 15, 1-3.	1.4	7
9	Prediction of pancreatic cancer risk and therapeutic response with next-generation sequencing. <i>Biomarkers in Medicine</i> , 2018, 12, 5-8.	0.6	3
10	Precision in personalized prediction-based medicine. <i>Personalized Medicine</i> , 2018, 15, 467-470.	0.8	0
11	Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. <i>Pharmacogenomics</i> , 2018, 19, 1303-1310.	0.6	0
12	Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. <i>Biomarkers in Medicine</i> , 2018, 12, 1197-1201.	0.6	3
13	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. <i>Drug Discovery Today</i> , 2018, 23, 1848-1872.	3.2	12
14	Precise predictive and therapeutic strategy for breast cancer. <i>Future Oncology</i> , 2018, 14, 1777-1780.	1.1	1
15	Breast cancer genome analysis in time and space: biomarker development strategy. <i>Biomarkers in Medicine</i> , 2018, 12, 547-550.	0.6	2
16	Novel translational therapeutic strategy by sequencing primary liver cancer genomes. <i>Future Oncology</i> , 2017, 13, 1049-1052.	1.1	3
17	Regorafenib: a newly approved drug for advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2017, 13, 1665-1668.	1.1	1
18	Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma. <i>Biomarkers in Medicine</i> , 2017, 11, 515-518.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Intratumor and circulating clonal heterogeneity shape the basis of precision breast cancer therapy. <i>Future Oncology</i> , 2017, 13, 113-116.	1.1	4
20	Molecular landscape of pancreatic cancer: challenges and clinical implications. <i>Future Oncology</i> , 2017, 13, 2741-2744.	1.1	1
21	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. <i>International Journal of Molecular Sciences</i> , 2017, 18, 180.	1.8	16
22	Primary liver cancer genome sequencing: translational implications and challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 875-883.	1.4	3
23	Intratumor heterogeneity: predicting and preventing therapeutic resistance. <i>Biomarkers in Medicine</i> , 2016, 10, 681-684.	0.6	2
24	Targeting dynamics of subclones of GI, liver and pancreatic cancers. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 773-776.	1.4	3
25	Palbociclib: an approval at last for HER2-negative breast cancer. <i>Future Oncology</i> , 2016, 12, 1097-1100.	1.1	4
26	Genome-based approaches for the diagnosis of breast cancer: a review with perspective. <i>Breast Cancer Management</i> , 2014, 3, 173-193.	0.2	0
27	Novel Next-Generation Sequencing and Networks-Based Therapeutic Targets: Realistic and More Effective Drug Design and Discovery. <i>Current Pharmaceutical Design</i> , 2014, 20, 11-22.	0.9	13
28	Targeted therapy for colorectal cancer resistance to EGF receptor antibodies and new trends. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 5-8.	1.4	3
29	Research and clinical applications of cancer genome sequencing. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 3-10.	0.9	14
30	Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era. <i>Future Oncology</i> , 2012, 8, 1373-1376.	1.1	1
31	Risk Factors and Early Detection of Breast Cancer: Facts, Questions, and Genome-Based Perspectives. <i>Current Oncology</i> , 2012, 19, 131-131.	0.9	1
32	Genome-based diagnostics and predictive tools: a new epoch for breast cancer management. <i>Future Oncology</i> , 2012, 8, 1211-1214.	1.1	0
33	Emerging personalized oncology: sequencing and systems strategies. <i>Future Oncology</i> , 2012, 8, 637-641.	1.1	16
34	Targeted therapy: overcoming drug resistance with clinical cancer genome. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 861-864.	1.1	4
35	Translating Cancer Genomes Sequencing Revolution into Surgical Oncology Practice. <i>Journal of Surgical Research</i> , 2012, 173, 365-369.	0.8	7
36	In Response: Tissue Expansion and Latissimus Dorsi Transfer for Arm Thorax Synechia (Reply). <i>Journal of Burn Care and Research</i> , 2011, 32, e179.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Tissue Expansion and Latissimus Dorsi Transfer for Arm-Thorax Synechia Reconstruction. Journal of Burn Care and Research, 2011, 32, e15-e20.	0.2	3
38	Quality Control in Laparoscopic Gastrectomy for Gastric Cancer—Measurement of Nodes Harvested?. Annals of Surgical Oncology, 2011, 18, 289-290.	0.7	1
39	From evidence to a day-to-day laparoscopic colectomy. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 985-987.	1.3	1
40	Laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis and impact of anti-tumor necrosis factor on postoperative outcomes. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 2057-2058.	1.3	0
41	Preventing Familial Breast and Ovarian Cancer: Major Research Advances with Little Implication. Women's Health, 2011, 7, 135-138.	0.7	1
42	From traditional molecular biology to network oncology. Future Oncology, 2011, 7, 155-159.	1.1	4
43	Omitting Axilla Lymphadenectomy Even by Positive Sentinel Lymph Node: A Change in Breast Cancer Treatment Practice. Women's Health, 2011, 7, 417-418.	0.7	3
44	Genome diagnostics: next-generation sequencing, new genome-wide association studies and clinical challenges. Expert Review of Molecular Diagnostics, 2011, 11, 663-666.	1.5	11
45	Pharmacogenomics for tailoring cardiovascular and anticancer drugs: from genotyping to whole-genome sequencing. Pharmacogenomics, 2011, 12, 1081-1085.	0.6	2
46	New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology. Expert Review of Anticancer Therapy, 2011, 11, 5-8.	1.1	3
47	Laparoscopic and Robotic Rectal Cancer Resection: Expectations for Improving Oncological Outcomes. Annals of Surgery, 2010, 251, 185-186.	2.1	11
48	Nipple-Sparing Mastectomy: Overcoming Oncological Outcomes Challenges. Annals of Surgical Oncology, 2010, 17, 323-324.	0.7	8
49	Node Micrometastases Detection After Neoadjuvant Chemotherapy in Breast Cancer: Is It of Clinical Value?. Annals of Surgical Oncology, 2010, 17, 933-934.	0.7	0
50	Limitations of Isolated Tumor Cells in Gastric Cancer: Heterogeneity Requests Systems Biology Approaches Towards Personalized Medicine. Annals of Surgical Oncology, 2010, 17, 343-344.	0.7	2
51	Searching for a Cutoff Value for Lymph Nodes Retrieved as a Quality Control of Surgery and Pathology in Colon Cancer. Annals of Surgical Oncology, 2010, 17, 325-326.	0.7	1
52	Caution in Adding Bevacizumab in the Adjuvant Treatment of Breast Cancer. Annals of Surgical Oncology, 2010, 17, 653-654.	0.7	0
53	Follow-Up for Gastric Cancer: How Extensive and Intensive Should It Be?. Annals of Surgical Oncology, 2010, 17, 941-941.	0.7	3
54	Micrometastatic Sentinel Lymph Node Disease: Do Patients Benefit or Suffer Harm from Axillary Lymph Node Dissection?. Annals of Surgical Oncology, 2010, 17, 936-937.	0.7	1

#	ARTICLE	IF	CITATIONS
55	Chemoradiotherapy in Adenocarcinoma of the Stomach or Esophagus. <i>Annals of Surgical Oncology</i> , 2010, 17, 1715-1716.	0.7	1
56	Mastectomy vs Breast-Conserving Surgery: An Old Dilemma Comes Again for Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 1966-1967.	0.7	2
57	Moving from Lymph Node Metastasis in Gastric Cancer to Biological Markers. <i>World Journal of Surgery</i> , 2010, 34, 1140-1141.	0.8	2
58	Robotic versus laparoscopic gastrectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 239-241.	1.3	5
59	Outweighing the benefits and weakness of endoscopic submucosal dissection for early gastric cancer in the west. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 1507-1509.	1.3	2
60	Open versus laparoscopic versus robotic gastrectomy for cancer: need for comparative-effectiveness quality. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 1510-1512.	1.3	4
61	Laparoscopic surgery for rectal cancer: the standard of care?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 2074-2075.	1.3	1
62	Laparoscopic total gastrectomy: further progress in gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 2355-2357.	1.3	6
63	Laparoscopic low vs. high anterior resection for rectal cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010, 24, 2359-2360.	1.3	0
64	Vascular pedicle avulsion in free flap breast reconstruction: A case of diep flap salvage following early avulsion of venous anastomosis and literature review. <i>Microsurgery</i> , 2010, 30, 233-237.	0.6	6
65	Colorectal cancer: cetuximab, <i>KRAS</i> , <i>BRAF</i> , <i>PIK3CA</i> mutations and beyond. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 525-529.	1.4	18
66	Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1187-1195.	1.1	19
67	From tumor size and <i>HER2</i> status to systems oncology for very early breast cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 123-128.	1.1	67
68	Robotic D2 surgery for gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 1919-1921.	1.3	3
69	Laparoscopic gastrectomy for organ-confined cancer: a reality in the west?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 1924-1926.	1.3	7
70	Beyond quality-of-life improvement: how robotic surgery for low anterior resection with total mesorectal excision also may improve oncologic outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2009, 23, 2662-2664.	1.3	5
71	Limitations of "Classic" Risk Factors to Predict Neoadjuvant Chemotherapy Response for Operable Breast Cancer. <i>World Journal of Surgery</i> , 2009, 33, 1545-1546.	0.8	1
72	Breast-Conserving Surgery in Asian Women: Benefits and Potential Harm. <i>World Journal of Surgery</i> , 2009, 33, 1548-1549.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Human Genetic and Structural Genomic Variation: Would Genome-Wide Association Studies Be the Solution for Cancer Complexity Like Alexander the Great for the "Gordian Knot"? Annals of Surgical Oncology, 2009, 16, 774-775.	0.7	91
74	Exploring Clinical Implications of Mechanisms for Breast Cancer Local Recurrence. Annals of Surgical Oncology, 2009, 16, 783-784.	0.7	1
75	Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery. Annals of Surgical Oncology, 2009, 16, 544-545.	0.7	0
76	Challenges in Developing Robust Genetic Markers and Targets to Predict and Prevent Distant and Peritoneal Recurrence in Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 1068-1069.	0.7	3
77	Is There a Role for Surgery in Recurrent Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 1074-1075.	0.7	4
78	Stage IV Breast Cancer: Is Surgical Resection of Clinical Utility?. Annals of Surgical Oncology, 2009, 16, 1437-1438.	0.7	3
79	Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?. Annals of Surgical Oncology, 2009, 16, 1063-1064.	0.7	6
80	Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical Practice. Annals of Surgical Oncology, 2009, 16, 1771-1782.	0.7	87
81	Isolated Tumor Cells in Sentinel Lymph Node and Clinical Implications for Early Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2659-2660.	0.7	0
82	Progress and Limitations of Surgery in Improving Outcomes of Esophagogastric Junction Cancer. Annals of Surgical Oncology, 2009, 16, 2074-2075.	0.7	3
83	Epigenetics in Gastric Cancer: Challenges for Clinical Implications. Annals of Surgical Oncology, 2009, 16, 2077-2078.	0.7	17
84	Local Excision for Rectal Cancer" Safety and Efficacy Challenges. Annals of Surgical Oncology, 2009, 16, 2369-2370.	0.7	3
85	The Decisive Role of Surgeon's Experience in Short-Term and Long-Term Oncological Outcomes and Quality of Life in Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 2377-2378.	0.7	2
86	Magnetic Resonance Imaging and Potential Impact on Extent of Surgery in Breast Cancer. Annals of Surgical Oncology, 2009, 16, 2953-2954.	0.7	0
87	Totally Laparoscopic Gastrectomy: A Reality for USA and Europe?. Annals of Surgical Oncology, 2009, 16, 2665-2666.	0.7	5
88	CDH1 Testing: Can it Predict the Prophylactic or Therapeutic Nature of Total Gastrectomy in Hereditary Diffuse Gastric Cancer?. Annals of Surgical Oncology, 2009, 16, 2678-2681.	0.7	75
89	Radiation burden of patients undergoing endovascular abdominal aortic aneurysm repair. Journal of Vascular Surgery, 2009, 49, 283-287.	0.6	71
90	Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer. Radiotherapy and Oncology, 2009, 90, 161-162.	0.3	5

#	ARTICLE	IF	CITATIONS
91	Highly elevated serum levels of CA 19-9 in choledocholithiasis: a case report. <i>Cases Journal</i> , 2009, 2, 6662.	0.4	19
92	Laparoscopic Colectomy Survival Benefit for Colon Cancer: Is Evidence From a Randomized Trial True?. <i>Annals of Surgery</i> , 2009, 249, 695-696.	2.1	51
93	Outcomes of breast cancer patients with and without BRCA1/2 mutations. <i>International Journal of Cancer</i> , 2008, 122, 1918-1919.	2.3	0
94	EGFR as a Prognostic Marker for Gastric Cancer. <i>World Journal of Surgery</i> , 2008, 32, 1225-1226.	0.8	11
95	Continuing Debate on D2 Lymphadenectomy for Gastric Cancer. <i>World Journal of Surgery</i> , 2008, 32, 2127-2128.	0.8	1
96	Robotic surgery for rectal cancer: may it improve also survival?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008, 22, 1405-1406.	1.3	65
97	Lymphadenectomy in Surgical Oncology. <i>Annals of Surgical Oncology</i> , 2008, 15, 386-387.	0.7	0
98	The Importance of Surgical Margin Control in Breast-Conserving Therapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 659-660.	0.7	1
99	Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy?. <i>Annals of Surgical Oncology</i> , 2008, 15, 943-944.	0.7	2
100	Advances in Laparoscopic Gastrectomy Expand Clinical Use. <i>Annals of Surgical Oncology</i> , 2008, 15, 1251-1252.	0.7	0
101	Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers. <i>Annals of Surgical Oncology</i> , 2008, 15, 1788-1790.	0.7	4
102	Controversy in the Treatment of Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 1795-1797.	0.7	3
103	Screening for or Prevention of Local Ipsilateral Recurrence and Contralateral Breast Cancer After Breast-Conserving Surgery?. <i>Annals of Surgical Oncology</i> , 2008, 15, 3617-3619.	0.7	0
104	Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 2352-2353.	0.7	1
105	Benefits, Limitations, and Harm of Local Excision for Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 2628-2629.	0.7	1
106	Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer—Promises and Reality. <i>Annals of Surgical Oncology</i> , 2008, 15, 2981-2982.	0.7	7
107	Lessons from Laparoscopic Gastrectomy: Preventing Surgical Complications. <i>Annals of Surgical Oncology</i> , 2008, 15, 2624-2625.	0.7	1
108	HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2008, 15, 3614-3615.	0.7	3

#	ARTICLE	IF	CITATIONS
109	Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. <i>Annals of Surgery</i> , 2008, 247, 714-715.	2.1	70
110	Intestinal obstruction due to an anomalous congenital band. <i>Saudi Journal of Gastroenterology</i> , 2008, 14, 36.	0.5	16